[Federal Register Volume 82, Number 205 (Wednesday, October 25, 2017)]
[Notices]
[Pages 49386-49387]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-23175]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Computer-Aided
Diagnosis of Prostate Cancer in Multi-Parametric MRI
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute and Clinical Center, institutes
of the National Institutes of Health, Department of Health and Human
Services, are contemplating the grant of an Exclusive Patent License to
practice the inventions embodied in the U.S. Patents and Patent
Applications listed in the SUPPLEMENTARY INFORMATION section of this
notice to ScanMed, LLC located in Omaha, NE.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before November 9, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be
[[Page 49387]]
directed to: Tedd Fenn, Senior Technology Transfer Manager, NCI
Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-
9702, Telephone: (240)-276-5530; Facsimile: (240)-276-5504, Email:
[email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent Application No. 62/462,256 filed
February 22, 2017 ``Computer-Aided Diagnosis of Prostate Cancer in
Multi-parametric MRI''
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of Licensed Patent Rights
for the following: ``Class II or III computer-assisted diagnostics
systems for use with Magnetic Resonance Imaging, of the anatomy of the
prostate.''
The subject technology is an automated computer assisted diagnostic
system for processing and visualizing prostate lesions on MRI. The
system uses specialized algorithms (an ensemble of multiple random
decision trees, Random Forest) that is trained against: (1) Hand drawn
contours, (2) recorded biopsy results, and (3) normal cases from
randomly sampled patient images weighted for lesion size. The system
produces a probability map of potential cancerous lesions in
multiparametric MRI.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice within the 15 days of this
notice, will be treated as objections to the grant of the contemplated
Exclusive Patent License Agreement. Comments and objections submitted
to this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: October 19, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2017-23175 Filed 10-24-17; 8:45 am]
BILLING CODE 4140-01-P